2013
DOI: 10.1371/journal.pone.0074107
|View full text |Cite
|
Sign up to set email alerts
|

A Phase II, Randomized, Double-Blind, Placebo Controlled, Dose-Response Trial of the Melatonin Effect on the Pain Threshold of Healthy Subjects

Abstract: BackgroundPrevious studies have suggested that melatonin may produce antinociception through peripheral and central mechanisms. Based on the preliminary encouraging results of studies of the effects of melatonin on pain modulation, the important question has been raised of whether there is a dose relationship in humans of melatonin on pain modulation.ObjectiveThe objective was to evaluate the analgesic dose response of the effects of melatonin on pressure and heat pain threshold and tolerance and the sedative … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
30
0
2

Year Published

2016
2016
2023
2023

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 32 publications
(34 citation statements)
references
References 37 publications
2
30
0
2
Order By: Relevance
“…At the level of physiological tests to assess pain, a doubleblind, randomized, placebo-controlled, dose-response experimental study investigated the analgesic effect of exogenous melatonin in humans. 11 The study included 60 volunteers and quantitative sensory testing (QST) was employed to measure pressure pain threshold/tolerance and pain threshold/tolerance. Sublingual melatonin (0.05 mg/kg; 0.15 mg/kg; 0.25 mg/kg) or placebo was administered 30 min before test procedures.…”
Section: Discussionmentioning
confidence: 99%
“…At the level of physiological tests to assess pain, a doubleblind, randomized, placebo-controlled, dose-response experimental study investigated the analgesic effect of exogenous melatonin in humans. 11 The study included 60 volunteers and quantitative sensory testing (QST) was employed to measure pressure pain threshold/tolerance and pain threshold/tolerance. Sublingual melatonin (0.05 mg/kg; 0.15 mg/kg; 0.25 mg/kg) or placebo was administered 30 min before test procedures.…”
Section: Discussionmentioning
confidence: 99%
“…Melatonin research has proliferated in many other specialties. Psychiatric problems like esquizofrenia (40), digestive (41), skin (33), metabolic (42) or respiratory problems (34), and particularly those that course with chronic inflammation (43) like rheumatologic (44) or autoimmune problems (45), or those related to cancer suffering (46), are some of them. All of these problems are due to circadian rhythms alterations and, because oxidative stress is inherent to the inflammatory process, melatonin has a great therapeutic potential for them (43).…”
Section: Discussionmentioning
confidence: 99%
“…This model has been used in clinical trials in pain related conditions other than SCD. 31-33,35 Current pain assessment measures in SCD are primarily focused on pain intensity (numeric rating scale, visual analog scale, faces scale) and pain frequency. These measures do not focus on qualitative aspects of pain nor dissect phenotypic variation of pain.…”
Section: Discussionmentioning
confidence: 99%